TDOC · XBRL financial data

Teladoc Health financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TDOC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	1,094	2,033	2,407	—	—	—
Revenue from contracts with customers	1,094	2,033	2,407	2,602	2,570	2,530
Cost of goods and services sold	391	650	744	—	—	—
Research and development	165	312	334	349	307	278
General and administrative	498	438	450	465	435	432
Operating income (loss)	(506)	(266)	(13,653)	(249)	(1,021)	(263)
Interest income	—	1	13	47	57	37
Interest expense	—	81	22	22	24	20
Other income (expense)	(1)	5	(1)	4	(6)	10
Income tax expense (benefit)	(91)	44	(4)	1	8	(35)
Net income (loss)	(485)	(429)	(13,660)	(220)	(1,001)	(200)
Earnings per share, basic USD per share	(5.36)	(2.73)	(84.60)	(1.34)	(5.87)	(1.14)
Earnings per share, diluted USD per share	(5.36)	(2.73)	(84.60)	(1.34)	(5.87)	(1.14)
Weighted average shares, basic millions of shares	91	157	161	165	171	176
Weighted average shares, diluted millions of shares	91	157	161	165	171	176

Fiscal years (TDOC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	733	893	918	1,124	1,298	781
Marketable securities	53	3	0	—	—	—
Accounts receivable	169	169	211	217	214	193
Inventory	56	73	56	30	38	38
Prepaid and other current assets	47	87	130	118	113	107
Total current assets	1,060	1,225	1,315	1,489	1,664	1,119
Property and equipment, net	29	27	30	32	29	27
Right-of-use asset	47	47	42	40	27	26
Goodwill	14,581	14,504	1,073	1,073	283	283
Total assets	17,755	17,735	4,345	4,392	3,517	2,858
Accounts payable	46	47	48	44	33	48
Current portion of long-term debt	43	0	—	—	—	—
Total current liabilities	333	331	400	421	942	405
Lease liability, non-current	43	42	38	43	32	34
Total liabilities	—	—	—	2,066	2,025	1,473
Accumulated deficit	(993)	(1,421)	(15,008)	(15,229)	(16,230)	(16,430)
Total stockholders' equity	15,884	16,046	2,308	2,326	1,491	1,386
Total liabilities and equity	17,755	17,735	4,345	4,392	3,517	2,858
Common shares outstanding (cover page) millions of shares	153	160	163	167	174	178

Fiscal years (TDOC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(485)	(429)	(13,660)	(220)	(1,001)	(200)
Stock-based compensation	476	303	218	202	146	80
Depreciation and amortization	69	204	256	—	—	—
Net cash from operating activities	(54)	194	189	350	294	294
Purchases of property and equipment	4	9	16	11	11	9
Net cash from investing activities	(591)	(73)	(168)	(156)	(124)	(266)
Proceeds from issuing common stock	0	—	—	—	—	—
Net cash from financing activities	859	41	6	11	8	(552)

SIC 8011 and related industry codes, similar size; rows marked “added: same SIC” fill a short list. Each row is the latest quarter reported.

How peers are chosen

SIC 8011 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Fewer than three companies fall in that range, so the list adds same-SIC (8011) companies nearest in public float, each marked “added: same SIC”.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Teladoc Health	850	605	106*	182.3M	—	Q3 FY26 10-QSep 30, 2026
LifeMD	25	47	(6.9)*	48.2M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Hims & Hers Healthadded: same SIC	610	753	(36)*	not reported	—	Q2 FY26 10-QJun 30, 2026
Starling Oncologyadded: same SIC	41	161	12*	101.9M	—	Q2 FY26 10-QJun 30, 2026
Airsculpt Technologiesadded: same SIC	19	43	(1.2)*	72.1M	15.2 quarters	Q2 FY26 10-QJun 30, 2026
SBC Medical Group Holdingsadded: same SIC	184	49	23*	102.8M	—	Q2 FY26 10-QJun 30, 2026
Cardiff Lexingtonadded: same SIC	0.2	2.2	(0.7)*	15.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
HealthLynkedadded: same SIC	0	not reported	(0.4)*	3.0M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Aunaadded: same SIC	236	year only	year only	not reported	—	Q4 FY24 20-F/ADec 31, 2024

Not investment advice. Not affiliated with the U.S. SEC.